Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L VanderBeek

Showing results (1-10 of 112) with videos related to

Pageof 12
Sort By:
JAMA Ophthalmology|September 23, 2021
Telemedicine and the Exacerbation of Health Care DisparitiesBrian L VanderBeek
JAMA Ophthalmology|February 15, 2019
The Argument for Sterile Loading of All Intravitreal Injections and the Benefit of Replicated ResultsBrian L VanderBeek
JAMA Ophthalmology|February 22, 2024
Toward Eliminating Visual Impairment Due to Refractive ErrorBrian L VanderBeek
JAMA Ophthalmology|June 5, 2025
Should We Be Concerned About Glucagon-Like Peptide-1 Receptor Agonists?Brian L VanderBeek
JAMA Ophthalmology|June 1, 2023
Difficulty in Assessing the Systemic Adverse Effects of Intravitreal Anti-Vascular Endothelial Growth Factor TherapyBrian L VanderBeek
JAMA Ophthalmology|October 24, 2024
Separating Supplement Effects From the Patients Who Use ThemBrian L VanderBeek
JAMA Ophthalmology|March 12, 2016
Oral Fluoroquinolones, Retinal Detachments, and Claims Database StudiesBrian L VanderBeek
Investigative Ophthalmology & Visual Science|May 21, 2014
Additional considerations in the utility of dark adaptometry for the diagnosis of age-related macular degenerationBrian L VanderBeek
Ophthalmology|April 25, 2020
Re: Ludwig et al.: Pentosan polysulfate sodium exposure and drug-induced maculopathy in commercially insured patients in the United States (Ophthalmology. 2020;127:535-543)Brian L VanderBeek, Nieraj Jain
JAMA Ophthalmology|January 13, 2022
Challenges in Elucidating Ophthalmology's Standards of Care: A ReviewAmy Hellem, Brian L VanderBeek
Pageof 12

Showing results (1-10 of 112) with videos related to

Sort By:
Pageof 12
JAMA Ophthalmology|September 23, 2021
Telemedicine and the Exacerbation of Health Care DisparitiesBrian L VanderBeek
JAMA Ophthalmology|February 15, 2019
The Argument for Sterile Loading of All Intravitreal Injections and the Benefit of Replicated ResultsBrian L VanderBeek
JAMA Ophthalmology|February 22, 2024
Toward Eliminating Visual Impairment Due to Refractive ErrorBrian L VanderBeek
JAMA Ophthalmology|June 5, 2025
Should We Be Concerned About Glucagon-Like Peptide-1 Receptor Agonists?Brian L VanderBeek
JAMA Ophthalmology|June 1, 2023
Difficulty in Assessing the Systemic Adverse Effects of Intravitreal Anti-Vascular Endothelial Growth Factor TherapyBrian L VanderBeek
JAMA Ophthalmology|October 24, 2024
Separating Supplement Effects From the Patients Who Use ThemBrian L VanderBeek
JAMA Ophthalmology|March 12, 2016
Oral Fluoroquinolones, Retinal Detachments, and Claims Database StudiesBrian L VanderBeek
Investigative Ophthalmology & Visual Science|May 21, 2014
Additional considerations in the utility of dark adaptometry for the diagnosis of age-related macular degenerationBrian L VanderBeek
Ophthalmology|April 25, 2020
Re: Ludwig et al.: Pentosan polysulfate sodium exposure and drug-induced maculopathy in commercially insured patients in the United States (Ophthalmology. 2020;127:535-543)Brian L VanderBeek, Nieraj Jain
JAMA Ophthalmology|January 13, 2022
Challenges in Elucidating Ophthalmology's Standards of Care: A ReviewAmy Hellem, Brian L VanderBeek
Pageof 12